106463-17-6 Usage
Description
Tamsulosin hydrochloride, also known as (R)-Tamsulosin, is a potent and selective antagonist of α1-adrenergic receptors (α1-ARs), specifically targeting the α1A and α1D adrenoceptor subtypes. It is the hydrochloride form of Tamsulosin and exists in two enantiomeric forms, with the R-isomer being the pharmaceutically active component. Tamsulosin hydrochloride is a white to off-white solid and is primarily used in the treatment of benign prostatic hyperplasia (BPH) and other related urinary conditions.
Uses
Used in Pharmaceutical Industry:
Tamsulosin hydrochloride is used as a specific α1-adrenoceptor antagonist for the treatment of benign prostatic hypertrophy. It helps reduce urinary obstruction and relieves symptoms associated with symptomatic BPH by blocking α1-adrenoceptors in the prostate, prostatic capsule, prostatic urethra, and bladder neck, leading to the relaxation of smooth muscles in these areas.
Used in Antineoplastic Applications:
Tamsulosin hydrochloride is also used as an antineoplastic and alkylating agent, demonstrating potential therapeutic effects in cancer treatment.
Used in Drug Delivery Systems:
Innovative drug delivery systems are being developed to enhance the applications and efficacy of Tamsulosin hydrochloride, particularly in the treatment of cancer. These systems aim to improve the delivery, bioavailability, and therapeutic outcomes of the drug by employing various organic and metallic nanoparticles as carriers.
References
https://www.drugbank.ca/drugs/DB00706
https://en.wikipedia.org/wiki/Tamsulosin
Originator
Contiflo OD,Ranbaxy Laboratories,India
Therapeutic Function
Antihypertensive
Hazard
Moderately toxic by ingestion.
Biological Activity
Selective α 1A -adrenoceptor antagonist (pK i values are 9.97, 9.64 and 8.86 for α 1A , α 1B and α 1D subtypes respectively). Decreases resting maximal urethral pressure with negligable effect on mean arterial blood pressure in vivo .
Biochem/physiol Actions
Tamsulosin is an α1A/1D-adrenoceptor antagonist used as a treatment of benign prostatic hypertrophy (BPH). Its activity as an ? blocker also affects the iris, and has led to complications during cataract surgery, a condition called "floppy iris" syndrome.
Check Digit Verification of cas no
The CAS Registry Mumber 106463-17-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,6,4,6 and 3 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 106463-17:
(8*1)+(7*0)+(6*6)+(5*4)+(4*6)+(3*3)+(2*1)+(1*7)=106
106 % 10 = 6
So 106463-17-6 is a valid CAS Registry Number.
InChI:InChI=1/C20H28N2O5S.ClH/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24;/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24);1H
106463-17-6Relevant articles and documents
Continuous-Flow Synthesis of (R)-Tamsulosin Utilizing Sequential Heterogeneous Catalysis
Ishitani, Haruro,Kobayashi, Shū,Laroche, Benjamin,Nishizawa, Ken,Saito, Yuki
, (2022/02/16)
We describe the continuous-flow synthesis of (R)-tamsulosin, a blockbuster therapeutic drug employed for dysuria associated with urinary stones and benign prostatic hyperplasia, by utilizing sequential heterogeneous catalysis. Two heterogeneous catalysts have been developed for the synthesis, and the key step involves reductive amination of nitriles using dimethylpolysilane-modified Pd on activated carbon/calcium phosphate. Overall, (R)-tamsulosin was obtained in 60 % yield and 64 % ee (99 % ee after recrystallization) in a flow stream through four catalytic transformations without the need for the isolation or purification of any intermediates or byproduct.
Process for the resolution of racemic (R,S) -5-(2-(2-(2- ethoxyphenoxy) ethylamino)propyl)-2-methoxybenzene sulfonamide (tamsulosin), its novel R and S isomers and their salts and processes for their preparation
-
Page/Page column 8; 9, (2010/10/20)
An improved process is described to resolve a racemic mixture in any proportion of 5-(2-(2-(2-ethoxyphenoxy)ethylamino)propyl)-2-methoxy benzene sulfonamide as a free base or some of its salts, with BPA either S or R form to obtain enantiomerically highly pure R and S-isomer as a well characterized free base or as a salt of the title compound. Also described are novel R and S-isomers of 5-(2-(2-(2-ethoxyphenoxy) ethylamino)propyl)-2-methoxy benzene sulfonamide and their salts and the processes for their preparation.
